|Day's Range||16.65 - 17.35|
|52 Week Range||10.50 - 19.90|
|PE Ratio (TTM)||-40.29|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox. The verdict by the jury in Boston came in a lawsuit by Cambridge, Massachusetts-based biotechnology company Momenta and its partner, Novartis AG's Sandoz unit, that sought nearly $940 million in damages. The jury found that while Rancho Cucamonga, California-based Amphastar had infringed Momenta's patent, it was invalid and unenforceable.
A federal jury has rejected a $938 million lawsuit filed by Momenta Pharmaceuticals that accused a California drugmaker of infringing its patent covering a generic blood-thinner. According to court records, the jury ruled Friday that while Amphastar Pharmaceuticals (AMPH) infringed Momenta’s (MNTA) patent for testing the quality of batches of the drug, the patent was invalid. Momenta and its partner, Novartis unit Sandoz, had sought $938 million in damages in the trial, which began July 11.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Momenta Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to MNTA-US. Comparing the performance and risk of Momenta Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)